Gabather’s target engagement study with the lead candidate GT-002, a treatment for neuropsychiatric disorders, is expected to produce its first results by the end of the year.
This according to the company’s CEO, Michael-Robin Witt, who joined BioStock for an interview. Gabather develops drugs aimed at treating a wide range of neuropsychiatric disorders, such as.